Pharming (PHAR) Consolidated Net Income (2020 - 2026)
Pharming (PHAR) posted Consolidated Net Income of -$4.5 million for Q1 2026, down 143.18% on a QoQ basis from $10.3 million in Q4 2025, and down 243.61% year-over-year from $3.1 million in Q1 2025.
Pharming (PHAR) Consolidated Net Income (2020 - 2026) Analysis & Trends
Pharming's Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$4.5 million for Q1 2026.
- Quarterly Consolidated Net Income fell 243.61% year-over-year to -$4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (up 149.99% YoY) and the FY2025 annual result came in at $2.5 million, up 121.43% from the prior year.
- Consolidated Net Income was -$4.5 million for Q1 2026 at Pharming, down from $10.3 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $37.9 million in Q4 2022 and bottomed at -$22.5 million in Q2 2024.
- A 5-year average of $751529.7 and a median of $1.5 million in 2024 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2023 — Consolidated Net Income tumbled 603.58% — and 2025, when it surged 300.47%.
- Pharming's Consolidated Net Income stood at $37.9 million in 2022, then tumbled by 135.56% to -$13.5 million in 2023, then jumped by 61.84% to -$5.1 million in 2024, then jumped by 300.47% to $10.3 million in 2025, then plunged by 143.18% to -$4.5 million in 2026.
- Business Quant data shows PHAR's Consolidated Net Income at -$4.5 million in Q1 2026, $10.3 million in Q4 2025, and $17.9 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Pharming | 9.02 Bn | 8.96 Bn | 65.80 Mn | -4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.45 Mn |
| Dec 31, 2025 | 10.31 Mn |
| Sep 30, 2025 | 17.90 |
| Jun 30, 2025 | 5.63 Mn |
| Mar 31, 2025 | 3.10 Mn |
| Dec 31, 2024 | -5.14 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | -22.45 Mn |
| Mar 31, 2024 | -4.18 Mn |
| Dec 31, 2023 | -13.48 Mn |
| Sep 30, 2023 | 3.15 Mn |
| Jun 30, 2023 | -15.69 Mn |
| Mar 31, 2023 | -18.13 Mn |
| Dec 31, 2022 | 37.90 Mn |
| Sep 30, 2022 | 9.50 Mn |
| Jun 30, 2022 | 21.59 Mn |
| Mar 31, 2022 | 3.60 Mn |
| Dec 31, 2021 | 15.19 Mn |
| Sep 30, 2021 | -17.81 Mn |
| Jun 30, 2021 | 12.22 Mn |